March 14, 2018—Randox Laboratories and Bosch Healthcare Solutions will unveil Vivalytic, a fully automated molecular diagnostics platform, at the 28th European Congress of Clinical Microbiology and Infectious Diseases, April 21–24, in Madrid.
Vivalytic supports end-point PCR, quantitative real-time PCR, melting curve analysis, and microarray technology, enabling singleplex, low-plex, and high multiplex testing on the same device. Depending on the test application, results are available in 30 minutes.
“This is transformational for patients and doctors; never before has there been this level of accessibility to such a wealth of molecular tests,” Peter FitzGerald, MD, founder and managing director of Randox, said in a statement. “Randox molecular assays continue to evolve, keeping precise diagnostics for targeted patient therapy at the center. With Vivalytic, there’s no limit to the testing portfolio that can be made available on its universal platform, and importantly it delivers results quickly and accurately.”
The first tests available on the Vivalytic are Randox’s panels for respiratory and sexually transmitted infections.